新埃立克体在接受肿瘤坏死因子抑制剂的风湿病患者与献血者中不常见:一项回顾性队列研究
本研究从丹麦风湿病生物样本库和丹麦献血者研究获取2015年至2022年间400例接受肿瘤坏死因子抑制剂(TNFi)治疗的风湿病患者与400名健康献血者的血浆样本,以groEL基因为靶点行实时PCR检测新埃立克体(Neoehrlichia mikurensis)DNA。结果所有样本均未检出该菌DNA,作者认为该感染在接受TNFi的丹麦风湿病患者及献血者中似乎不构成常见风险。
要点
- 400例接受TNFi的风湿病患者与400名献血者血浆样本中均未检出N. mikurensis DNA。
- 风湿病患者中位年龄61岁(IQR 55-68岁),62%为女性,44%为血清阳性类风湿关节炎。
- 54%的患者使用英夫利西单抗,TNFi启动至采血中位时间20个月(IQR 5-60个月)。
核心结论
- 作者认为,N. mikurensis感染在接受TNFi的丹麦风湿病患者或献血者中似乎不构成常见风险。
研究设计与样本
- 回顾性队列研究,纳入400例接受TNFi治疗的风湿病患者和400名健康献血者。
- 血浆样本取自丹麦风湿病生物样本库和丹麦献血者研究,采样时间为2015年至2022年。
- 每例取一份血浆样本,采用针对groEL基因的N. mikurensis DNA特异性实时PCR检测。
- 年龄、性别、诊断和TNFi治疗时长来自丹麦风湿病数据库DANBIO;献血者仅有年龄和性别数据。
主要发现
- 风湿病患者中位年龄61岁(IQR 55-68岁),62%为女性,44%诊断为血清阳性类风湿关节炎。
- 54%的风湿病患者接受英夫利西单抗治疗,TNFi启动至采血的中位时间为20个月(IQR 5-60个月)。
- 患者与献血者样本中均未检出N. mikurensis DNA。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Neoehrlichia mikurensis is a tick-borne bacterium that primarily causes disease in immunocompromised patients. The bacterium has been detected in ticks throughout Europe, with a 0%-25% prevalence. N. mikurensis infection presents unspecific symptoms, which can easily be mistaken for inflammatory disease activity. We aimed to determine the prevalence of N. mikurensis in rheumatological patients receiving tumour necrosis factor inhibitors (TNFi) and a cohort of healthy individuals. MATERIALS AND METHODS: This retrospective cohort study included 400 rheumatological patients treated with TNFi and 400 healthy blood donors. Plasma samples were retrieved from the Danish Rheumatological Biobank and the Danish Blood Donor Study between 2015 and 2022. Age, sex, diagnosis and duration of TNFi treatment were recovered from the Danish Rheumatological Database, DANBIO. Data on age and sex were available for the blood donors. One plasma sample per individual was tested for N. mikurensis DNA-specific real-time PCR targeting the groEL gene. RESULTS: In the rheumatological patients, the median age was 61 years (IQR 55-68 years), 62% were women, and 44% had a diagnosis of seropositive rheumatoid arthritis. In total, 54% of the patients were treated with infliximab. The median time from TNFi initiation to blood sampling was 20 months (IQR, 5-60 months). N. mikurensis DNA was not detected in any samples from patients or blood donors. CONCLUSION: N. mikurensis infection does not appear to represent a prevalent risk in Danish rheumatological patients receiving TNFi or in blood donors.
引用
- Gynthersen R, Ørbæk M, Høgdall E, et al. Neoehrlichia mikurensis is uncommon in rheumatological patients receiving tumour necrosis factor inhibitors and in blood donors: a retrospective cohort study. RMD Open. 2024. PMID: 38176737. doi:10.1136/rmdopen-2023-003660
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。